Elicera Therapeutics develops new cell therapy treatments based on the enhancement of validated techniques. Major focus is on the CAR-T area where the market is expected to multiply in the coming years. Elicera intends to address rare cancers such as lymphoma and brain cancer, which opens for potentially faster clinical development than the average drug project.
| Homepage: | www.elicera.com |
| Initial coverage: | December 13, 2021 |
| Industry: | Biotech |
| List: | Nasdaq OMX, First North |
| Ticker: | ELIC:SS |
December 13, 2021 Initial coverage: Cell therapy under the radar
